Viking Therapeutics Inc — movimiento trimestral de fondos (NASDAQ:VKTX) | MetaTrader

Ver el calendario completo

Financials

Visión general Informes Estadísticas

Activos totales 908.32 M866.99 M827.85 M739.41 M715.73 M Total de pasivos 28.04 M20.07 M32.39 M26.39 M76.67 M Capital total 880.28 M846.92 M795.46 M713.03 M639.06 M Total de pasivos y patrimonio neto 908.32 M866.99 M827.85 M739.41 M715.73 M Deuda total ————— Deuda neta —————

Noticias

How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q1 Results?

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

Viking Therapeutics, Inc. (VKTX) Surpasses Market Returns: Some Facts Worth Knowing

NVO Crashes 36% in 3 Months: Is This an Indication to Sell the Stock?

LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships

3 Best Stocks Under $50 to Buy in April 2026, According to Analysts - TipRanks.com

Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?

WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks

VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug

Morgan Stanley reitera calificación de Viking Therapeutics por avances en ensayos